Kyle Holen, Globl Head of Clinical Sciences at Takeda, shared a post on LinkedIn:
”I am thrilled to share that I have joined Takeda Oncology as the Global Head of Clinical Sciences – and I could not be more energized for what lies ahead.
Takeda’s story is one of the most remarkable in the history of medicine. Founded in 1781 in Osaka, Japan, the company has spent nearly two and a half centuries dedicated to the pursuit of better health and a brighter future for patients worldwide. That legacy is not just a point of pride – it is a living, breathing commitment that shapes every decision made within this organization.
In recent years, Takeda has made extraordinary strides in oncology – advancing a diverse and promising pipeline spanning a wide variety of hematologic and solid tumor malignancies. The science is bold, the technology is cutting-edge, and the ambition is exactly what patients deserve.
What excites me most is the opportunity to work alongside a team of executives with deep oncology expertise, and at a company with the resources and resolve to robustly interrogate every asset in its pipeline.
This is the kind of environment where the best science wins – and where that science can genuinely change lives.
A heartfelt thank you to Andy Plump, PK Morrow, and Teresa Bitetti for this incredible opportunity and for the vision and leadership you bring to oncology every single day. I am humbled and inspired to be in such exceptional company.
The best is yet to come. Let’s make oncology history.”
Other Articles on OncoDaily.